Fundamental dimension Equity attribute | CBDYLeader $0.0010.00% Cap $617.0KP/E -0.3x QuantScore38/100 | ALIDPeer $0.00050.00% Cap $57.75KP/E -0.0x QuantScore38/100 | BINPPeer $0.03▼-0.00% Cap $1.62MP/E -6.0x QuantScore27/100 |
|---|---|---|---|
1. QuantScore pillars0–100 per pillar · click a ticker for the factor breakdown | |||
Technical | |||
75/100 |
73/100 |
50/100 |
Valuation Multiples, PEG & DCF upside | 50/100 | 33/100 | 40/100 |
Health Piotroski, Altman Z, leverage & liquidity | 20/100 | 20/100 | 20/100 |
Growth Revenue / earnings growth & margins | 9/100 | 26/100 | 0/100 |
Sentiment Analyst ratings, targets & revisions | — | — | — |
2. Valuation multiples & capital pricingGreen highlight = best-in-class (lowest positive multiple) |
Trailing P/E | -0.3x | -0.0x | -6.0x |
Forward P/E (next FY) | — | — | — |
EV / EBITDA (TTM) | 98.7x | -0.9x | 3.2x |
Price / Sales | 0.2x | 0.8x | — |
Price / Free Cash Flow | -0.6x | -0.0x | 7042.8x |
PEG ratio | 0.00 | 0.00 | 0.05 |
3. Financial health & solvencyLatest filings |
Piotroski F-Score | 1 / 9 | 2 / 9 | 1 / 9 |
Altman Z-Score | -10.35 (Distress) | -48.13 (Distress) | -0.57 (Distress) |
Total debt / equity | -1.29 | -0.85 | -1.84 |
Quick ratio | 0.0x | 0.0x | 0.3x |
Interest coverage | -0.3x | -11.9x | -167.8x |
4. Growth & margins trajectoryLatest fiscal year |
Revenue growth YoY | -41.1% | -56.5% | -100.0% |
Net income growth YoY | -947.1% | +36.4% | -2803.6% |
Gross margin (TTM) | 32.9% | -2027.5% | 0.0% |
Operating margin (FY) | 48.1% | -14235.4% | — |
FCF margin (FY) | -23.6% | -2835.9% | — |
5. Trailing price performancePrice change over period |
1M return | +11.1% | -0.0% | 0.0% |
3M return | -16.7% | -0.0% | +50.0% |
6M return | -35.5% | -0.0% | +48.5% |
Year to date | -33.3% | -0.0% | 0.0% |
1Y return | -43.2% | -95.5% | -89.3% |
3Y return | -60.8% | -99.6% | -97.0% |
6. DCF valuation & street consensusDCF model · analyst consensus |
DCF model fair value | $0.0109 +993.1% upside | $-0.0786 -15825.2% premium | $-0.0088 -129.3% premium |
Wall Street consensus target | — — | — — | — — |
Consensus stance | — | — | — |